Current Therapeutics For Cardiac Amyloidosis

Home
»
2024 Fall Conference
»
Product Details

You must select a location to proceed.

Yes

There was a problem adding this course to your account. Please try again in a few minutes. If the problem persists, you can contact our support department at (877) 880-1335.

Adding Registration, Please wait...

You must be logged in to perform this action.

Cancel

Current Therapeutics For Cardiac Amyloidosis

Recorded for 2024 Fall Conference

Credit(s):

0.87 Contact Hour(s) of CE; all of which may be applied towards Pharmacology

Program Number:

24096862

Original Program Date:

September 22, 2024

Duration:

52 minutes

Access:

Available until October 15, 2025

Special Offer

Click here to see Special Offer(s)!

Facebook

E-Mail

Description
Sessions
Credits
Faculty
Materials
Reviews
Dates and Locations

(341)

Read Reviews

Category: 2024 Fall Conference, Adult-Gerontology, Cardiology ... (show more)

Category: 2024 Fall Conference, Adult-Gerontology, Cardiology, Cardiometabolic, Cardiovascular, Cert Exam Domain - Planning, Expiring Soon, Outpatient (show less)

Subcategory: Planning

Subcategory: Planning
(show less)

Activity Duration

Content Expires:

October 15, 2025 (11:55 p.m. CT)
CE for this activity will not be available after this date.

This CE activity was recorded for the 2024 AANP Fall Conference.

This activity includes closed captioning.

Delivery Note: The content for this activity was previously presented during the 2024 AANP Fall Conference. If you already completed the content of this activity while attending the live or virtual conference, you should not complete this content a second time. Learners should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is considered duplicate credit for the same content and will not be accepted by regulatory bodies.

Overview
This presentation addresses the pharmacological management of cardiac amyloidosis, highlighting treatments for both transthyretin (ATTR) and light-chain (AL) types. We will review targeted therapies such as TTR stabilizers and silencers for ATTR, and chemotherapy options for AL, discussing their mechanisms and clinical outcomes. Additionally, the session will cover essential symptom management strategies, including the use of diuretics and beta-blockers to alleviate heart failure symptoms common in amyloidosis patients. The presentation aims to provide a comprehensive overview of current and emerging treatments, emphasizing a multidisciplinary approach to enhancing patient care and outcomes in cardiac amyloidosis. This session is designed for Health Care professionals seeking to deepen their understanding of these complex therapeutic strategies and their practical applications in clinical settings.

Objectives

Identify the various types of cardiac amyloidosis and the specific medications used for each type.
Explore the mechanisms of action, therapeutic uses, and side effects of different medications with focus on their application in treating cardiac amyloidosis.
Analyze the effectiveness and limitations of existing medications for cardiac amyloidosis.
Evaluate the outcomes of different medication regimens on patient survival and quality of life in cardiac amyloidosis.

Speaker
Tracy Joshi, DNP, FNP, RN

Disclosure
This program was planned in accordance with AANP CE Standards and Policies.

The speaker has the following disclosures:

I have nothing to disclose.

Disclaimer
Individuals who have contributed to the CE Center (content originally from the 2024 AANP Fall Conference) were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

CE Credit Instructions

Read this activity description, including objectives and disclosures.
Complete all educational content:
- OnDemand Presentations: Click the Play button to watch the activity video lecture. To get full credit for the learning activity portion, you must watch all of the video content.
- Click on the Additional Resources button to review all additional materials provided (handouts and any other downloadable resources).
After completing all educational content, go to the Next Steps button:
- Submit the activity evaluation to receive full AANP CE/Rx credit.
- Click on the Get Certificate button. At the top of the certificate screen, use the provided dropdown menu and select AANP Certificate of Completion.
  - A copy of your certificate of completion will display on the screen for you to print or save. A copy of the certificate will also be emailed to you.
  - A copy of the certificate will be automatically added to your AANP CE Tracker.

Additional Information
For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.

0.87 Contact Hour(s) of CE,
All of which may be applied towards Pharmacology